908 Devices Announces Significant Milestones
News Aug 20, 2014
908 Devices announced a number of significant milestones since the introduction of its flagship product, M908™, the world’s first and only handheld tool utilizing high-pressure mass spectrometry™ (HPMS) for trace-level chemical detection and identification.
The company's facility is strategically located in Boston’s Innovation District on DryDock Avenue – an area undergoing radical transformation, attracting Boston’s most creative firms and tech companies. The new space includes a full machine shop, analytical and R&D labs, clean room, and collaborative meeting areas, allowing the team to create new concepts, prototypes, and manufacture product in-house, all under one roof. The expansion to a full production facility also provides the company with flexibility as it continues to grow and penetrate new markets. By designing and manufacturing products in-house, the team will stay actively involved in every stage of development, design verification, and manufacturing quality.
Since unveiling the powerful capabilities of HPMS in March 2014 with the introduction of M908, 908 Devices has recognized significant company momentum, which includes:
• Joe Griffith being appointed Chief Financial Officer, bringing his 17-year management background in corporate and operational finance, accounting and administration to 908 Devices. Joe previously served as CFO for PerkinElmer’s Life Science & Technology division and as CAO for Caliper Life Sciences.
• Expansion to 908 Device’s science and engineering staff to ramp up product development efforts for energy, environmental, and life science markets.
• To fuel the companies continued growth, the team has increased from its seven initial founders in 2012 to 30+ employees today with an expected 50% increase in 2015.
• The company is a recipient of the Mass Life Sciences Center award, providing up to $25 million in tax incentives for companies who are committed to creating new jobs in the Commonwealth and those who currently engaged in life sciences research and development.
“2014 is a banner year for 908 Devices, marked with tremendous growth and success,” said Dr. Kevin J. Knopp, co-founder and CEO, 908 Devices. “Within the analytical instrumentation industry, there has been an incredible shift in demand from very complex catch-all laboratory systems to purpose-built and user-centric analytical tools. The momentum of M908 demonstrates that we are meeting this need and we will continue to focus on delivering the best-in-class devices and solutions for our safety and security customers to use in the field. In addition, we see a lot of opportunity to expand our HPMS platform technology into exciting new applications, including energy, environmental monitoring, and life sciences. We are very fortunate to have been able to assemble some incredible talent to bring the most impactful technology out-of-the-lab in order to deliver meaningful results and create simplified tools out of mass spectrometry for these industries.”
“This is an exciting time to be joining 908 Devices,” said Joe Griffith, CFO, 908 Devices. “The success of M908 combined with the recent expansion to a full-scale production facility demonstrates that 908 Devices is poised to make a huge impact on mass spectrometry in the safety and security market and beyond. This is one of the most talented, forward thinking teams in the industry and I believe I can only help to propel the company forward as we build out infrastructure and processes to support our growth and strategic initiatives. I am honored to be joining the team and look forward to contributing to the company’s continued success.”
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE